Table 5. Summary of previously reported TINT factors in human prostate cancer patients that relate to patient outcome.

Factor in TINT	Tumor Gleason score*	Tumor clinical stage*	Estimated tumor size*
Epithelial pAKT [19]	R = 0.13, n = 240, p = 0.04	R = 0.14, n = 238, p = 0.03	R = 0.17, n = 240, p = 0.007
Stroma PDGFR-beta [23]	R = 0.15, n = 355, p = 0.004	R = 0.11, n = 349, p = 0.033	R = 0.16, n = 355, p = 0.003
Epithelial LRIG1 [24]	R = 0.18, n = 191,p = 0.014	R = 0.14, n = 190, p = 0.049	R = 0.20, n = 191, p = 0.006
Epithelial pEGFR [17]	R = 0.26, n = 174, p = 0.000	Non-correlated	Non-correlated
Stroma Mast cells [14]	R = 0.15, n = 358, p = 0.01	Non-correlated	Non-correlated
Stroma Hyaluronan [16]	R = 0.21, n = 216, p = 0.002	Non-correlated	Non-correlated
Stroma CD163+ macrophages [25]	R = 0.19, n = 105, p = 0.049	Non-correlated	Non-correlated
Stroma blood vessels [26]	Non-correlated	Non-correlated	Non-correlated
Stroma S100A9+ macrophages [20]	Non-correlated	Non-correlated	Non-correlated

*Association (R, Spearman rho) with TINT factor (n = number of patients examined).